After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...